DaclatasvirBrand Name: Daklinza Other Names: DCV, daclatasvir dihydrochloride Drug Class: Opportunistic Infections and Coinfections
What is daclatasvir?
Daclatasvir is a prescription medicine approved by the U.S.(FDA) for the treatment of chronic (lasting a long time) . Daclatasvir is used in combination with other medications and should not be taken by itself.
HCV is an. An opportunistic is an infection that occurs more frequently or is more severe in people with weakened immune systems—such as those infected with HIV—than in people with healthy immune systems.
How is daclatasvir used in people with HIV?
The Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, prepared by the(CDC), the (NIH), and the HIV Medicine Association of the Diseases Society of America (IDSA-HIVMA), and the C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected with Hepatitis C , prepared by the American Association for the Study of Diseases (AASLD), the Infectious Diseases Society of America (IDSA), and the International Antiviral Society-USA (IAS-USA), both include recommendations on the HIV-related uses of daclatasvir to treat chronic HCV infection.
In addition to recommendations for the medicine's use in treating chronic HCV infection, the guidelines and the guidance include recommendations on the “off-label” use of daclatasvir to treat acute HCV infection in HIV-infected individuals. “Off-label” use refers to use of an FDA-approved medicine in a manner different from that described on the medicine label. Good medical practice and the best interests of a patient sometimes require that a medicine be used “off-label.”
What should I tell my health care provider before taking daclatasvir?
Before taking daclatasvir, tell your health care provider:
- If you are allergic to daclatasvir or any other medicines.
- About any other medical conditions you have or have had, especially heart problems, liver transplant, or liver problems other than HCV infection.
- About anything that could affect your ability to take medicines, such as difficulty swallowing or remembering to take tablets.
- If you are pregnant or plan to become pregnant. Whether daclatasvir can harm an unborn baby is unknown. Talk to your health care provider about possible risks with taking daclatasvir when pregnant. Sometimes daclatasvir is taken with the HIV medicine ribavirin. Ribavirin may cause birth defects or death of an unborn baby. Pregnant women and men whose partners are pregnant should not use daclatasvir with ribavirin. Women should also not become pregnant for 6 months after they stop taking ribavirin or for 6 months after their male partners stop taking ribavirin.
- If you are breastfeeding or plan to breastfeed. Do not breastfeed if you are infected with HIV.
- About other prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Daclatasvir may affect the way other medicines or products work, and other medicines or products may affect how daclatasvir works. Ask your health care provider if there are interactions between daclatasvir and the other medicines you take.
Ask your health care provider about possible side effects from daclatasvir. Your health care provider will tell you what to do if you have side effects.
How should I take daclatasvir?
Take daclatasvir according to your health care provider’s instructions. Your health care provider will tell you how much daclatasvir to take and when to take it. Before you start daclatasvir and each time you get a refill, read any printed information that comes with your medicine.
How should daclatasvir be stored?
- Store daclatasvir at room temperature, 68°F to 77°F (20°C to 25°C).
- Do not use daclatasvir if the original seal over the bottle opening is broken or missing.
- Throw away daclatasvir that is no longer needed or expired (out of date). Follow FDA guidelines on how to safely dispose of unused medicine.
- Keep daclatasvir and all medicines out of reach of children.
Where can I find more information about daclatasvir?
More information about daclatasvir is available:
- Recommendations on the HIV-related uses of daclatasvir, from the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, prepared by CDC, NIH, and IDSA-HIVMA.
- Recommendations on the HIV-related uses of daclatasvir, from the Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected with Hepatitis C Virus, prepared by AASLD, IDSA, and IAS-USA.
- Daclatasvir-related research studies, from the database of study summaries.
The above Patient Version drug summary is based on the following FDA label(s): Tablet.
Last Reviewed: May 18, 2016